Drug Trial Radar · NCT04817956
Improving Public Cancer Care by Implementing Precision Medicine in Norway
Last checked: Nov 19, 2026Latest source record: Feb 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
3,000
Planned (sponsor's estimate)
Start
Apr 1, 2021
Primary completion
Mar 30, 2040
Study completion Apr 30, 2045
Sponsor
- Lead sponsor
- Oslo University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Haukeland University Hospital; St. Olavs Hospital; University Hospital of North Norway; University Hospital, Akershus; Vestre Viken Hospital Trust; Hospital of Southern Norway Trust; Ostfold Hospital Trust; The Hospital of Vestfold; Helse Stavanger HF; Nordlandssykehuset HF; Sykehuset Innlandet HF; Helse Forde; Helse Fonna; Helse Nord-Trøndelag HF; Helse Møre og Romsdal HF; Sykehuset Telemark; Lovisenberg Diakonale Hospital
- First posted
- Mar 26, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
IMPRESS-Norway is a prospective, non-randomized clinical trial evaluating efficacy of commercially available, anti-cancer drugs prescribed for patients with advanced cancer diagnosed with potentially actionable alterations as revealed by molecular diagnostics. IMPRESS-Norway is a nation-wide study and all hospitals with an oncology and / or hematology department will be invited to participate in the study. The study will use a combined umbrella and basket design and a Simon two-stage model of expanding cohorts to follow up potentially effective combinations of biomarker and drug on specific indications. Sampling of biological material will be performed at presentation, during treatment and upon progression. Additional biomarker and translational analyses including whole genome sequencing (WGS) on tumour material and liquid biopsies, identifying mechanisms underlying drug sensitivity versus resistance will be performed.
Conditions
- Cancer Metastatic
Interventions
AtezolizumabDrug
drugs used outside indication, based on biomarker
Primary outcomes
What the sponsor says the trial is designed to measure.
- 16 weeks clinical responseTime frame: 16 weeks
- Access to drugs for patientsTime frame: 4 years
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
Sykehuset Ålesund
Ålesund, Norway · Not yet recruiting
Haukeland universitetssykehus
Bergen, Norway · Recruiting
Nordlandssykehuset
Bodø, Norway · Recruiting
Vestre Viken Hospital
Drammen, Norway · Recruiting
Førde Hospital
Førde, Norway · Recruiting
Sykehuset Innlandet
Hamar, Norway · Recruiting
Helse Fonna
Haugesund, Norway · Not yet recruiting
Sørlandet sykehus
Kristiansand, Norway · Recruiting
Sykehuset Levanger
Levanger, Norway · Not yet recruiting
Oslo University Hospital
Oslo, Norway · Recruiting
Ahus
Oslo, Norway · Recruiting
Sykehuset Telemark
Skien, Norway · Recruiting
Stavanger universitetssykehus
Stavanger, Norway · Recruiting
Sykehuset Vestfold
Tønsberg, Norway · Not yet recruiting
Universitetssykehuset i Nord-Norge
Tromsø, Norway · Recruiting
St Olavs Hospital
Trondheim, Norway · Recruiting
Sykehuset Østfold Kalnes
Fredrikstad, Østfold fylke, Norway · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.